PAVmed Inc. (PAVM) News
Filter PAVM News Items
PAVM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PAVM News Highlights
- For PAVM, its 30 day story count is now at 3.
- Over the past 7 days, the trend for PAVM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- LUCD and RPM are the most mentioned tickers in articles about PAVM.
Latest PAVM News From Around the Web
Below are the latest news stories about PAVMED INC that investors may wish to consider to help them evaluate PAVM as an investment opportunity.
The 3 Most Undervalued Penny Stocks to Buy in DecemberWhen economies are set to boom, undervalued penny stocks typically lead the way when it comes to equity rallies. |
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility StudiesLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published— |
PAVmed Provides Additional Details for Upcoming Stock Dividend to ShareholdersPAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously announced dividend of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) for PAVmed shareholders. |
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger PotentialThere are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. |
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock SplitPAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid. |
Top Penny Stocks for Q4 2023Top penny stocks this month include Myomo Inc., Expion360 Inc., and Akebia Therapeutics Inc., all of which have more than tripled in value this last year. |
PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call TranscriptPAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s remarks, there will be an opportunity to ask questions. [Operator Instructions] Please also note that today’s event […] |
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call TranscriptLucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note that this event is being recorded. I would now like to turn the conference over […] |
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting EffortsLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), announced that the Company has strengthened and expanded its executive team with two industry veterans to support its critical market access and direct contracting efforts. Natalie S. Carfora joins Lucid as Vice President, Market Access, and James M. Fricchione as Vice President, Employe |
PAVmed Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsPAVmed ( NASDAQ:PAVM ) Third Quarter 2023 Results Key Financial Results Net loss: US$17.7m (loss narrowed by 32% from... |